SELLAS Life Sciences drew fresh attention after presenting new preclinical data on its CDK9 inhibitor, SLS009, in pancreatic cancer models at the AACR conference. The company’s stock has risen approximately 167% year to date.
The rally has prompted questions about SELLAS’s valuation. At the last close, shares were $11.61. The stock trades at a price-to-book ratio of 17x, compared with 2.1x for the broader US Biotechs group and a 4.4x average for its peer set. That premium suggests investors are pricing in high expectations for future progress rather than current financial performance. The company reported a net loss of $32.461 million and minimal revenue.